JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

Home・Akciju saraksts・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Slēgts

28.59 0.78

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

28.04

Max

28.99

Galvenie mērījumi
By Trading Economics
Ienākumi	-30M -30M
Pārdošana	-26M 77M
Peļņas marža	-38.823
Darbinieki	524
EBITDA	-12M -8M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+119.43% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-212M 1.5B
Iepriekšējā atvēršanas cena	27.81
Iepriekšējā slēgšanas cena	28.59

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

27.895 / 30.16 Atbalsts un pretestība

Immunocore Holdings PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 28. apr. 23:33 UTC

Karstas akcijas

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

2026. g. 28. apr. 23:24 UTC

Peļņas

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

2026. g. 28. apr. 23:15 UTC

Galvenie ziņu notikumi

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

2026. g. 28. apr. 22:46 UTC

Peļņas

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

2026. g. 28. apr. 22:37 UTC

Peļņas

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

2026. g. 28. apr. 22:15 UTC

Peļņas

Galvenie ziņu notikumi

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

2026. g. 28. apr. 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

2026. g. 28. apr. 23:31 UTC

Peļņas

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

2026. g. 28. apr. 23:31 UTC

Peļņas

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

2026. g. 28. apr. 23:30 UTC

Peļņas

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

2026. g. 28. apr. 23:30 UTC

Peļņas

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

2026. g. 28. apr. 23:19 UTC

Tirgus saruna

Peļņas

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

2026. g. 28. apr. 23:09 UTC

Peļņas

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

2026. g. 28. apr. 23:03 UTC

Tirgus saruna

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

2026. g. 28. apr. 23:01 UTC

Galvenie ziņu notikumi

NIESR Sees One Rate Rise to 4% in Benign Scenario

2026. g. 28. apr. 23:01 UTC

Galvenie ziņu notikumi

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

2026. g. 28. apr. 23:01 UTC

Galvenie ziņu notikumi

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

2026. g. 28. apr. 23:01 UTC

Galvenie ziņu notikumi

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

2026. g. 28. apr. 23:01 UTC

Galvenie ziņu notikumi

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

2026. g. 28. apr. 22:51 UTC

Peļņas

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

2026. g. 28. apr. 22:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 28. apr. 22:48 UTC

Tirgus saruna

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

2026. g. 28. apr. 22:40 UTC

Tirgus saruna

Galvenie ziņu notikumi

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

2026. g. 28. apr. 22:32 UTC

Peļņas

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

2026. g. 28. apr. 22:25 UTC

Iegādes, apvienošanās, pārņemšana

Pernod Ricard and Brown-Forman End Deal Talks -- Update

2026. g. 28. apr. 22:22 UTC

Peļņas

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

2026. g. 28. apr. 22:17 UTC

Tirgus saruna

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

2026. g. 28. apr. 22:14 UTC

Peļņas

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

2026. g. 28. apr. 22:14 UTC

Peļņas

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

2026. g. 28. apr. 22:07 UTC

Tirgus saruna

Galvenie ziņu notikumi

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Salīdzinājums

Cenas izmaiņa

Immunocore Holdings PLC ADR Prognoze

Cenas mērķis

By TipRanks

119.43% augšup

Prognoze 12 mēnešiem

Vidējais 62.67 USD 119.43%

Augstākais 100 USD

Zemākais 33 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

9 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 9 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

27.895 / 30.16Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.